{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:16:35Z","timestamp":1777907795185,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>Depression is not a unitary disease and not all cases of depression can be\ntreated alike. Therefore, predictors of antidepressant response to different drugs need to be\nidentified. Premorbid personality, age and sex and family history are useful in prediction. As\nan example, only females respond to the addition of triiodothyronine to the antidepressant\ntherapy. Endogenous depressions respond favourably to antidepressants, so also do psychotic\ndepressions. On the other hand, delusional depressions do not respond to antidepressants.\nWhile atypical depressions are best treated with MAOI, motor retardation improves\nwith imipramine and obsessive symptoms with chlorimipramine. In addition to clinical\nvariables, biochemical and statistical approaches have also yielded significant results in prediction.<\/jats:p>","DOI":"10.1159\/000468325","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:20:03Z","timestamp":1502472003000},"page":"69-93","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Prediction of Antidepressant Response"],"prefix":"10.1159","author":[{"given":"J.","family":"Ananth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:47:51Z","timestamp":1777643271000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468325","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}